Here are the DEF 14A proxy statements from Enveric Biosciences, Inc. (ENVB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Enveric Biosciences, Inc. has called its 2026 annual stockholder meeting for May 28, 2026 at 10:00 a.m. Eastern Time, to be held exclusively online via live webcast. Stockholders of record as of March 30, 2026, when 1,887,535 shares of common stock were outstanding, may vote.
Investors are asked to elect six directors, cast an advisory “say‑on‑pay” vote on executive compensation, and extend prior approvals that give the board flexibility to effect a reverse stock split within a specified range and to increase authorized common shares from 100,000,000 to 5,000,000,000. The agenda also includes ratifying CBIZ CPAs P.C. as independent auditor for 2026 and approving potential adjournment to solicit additional proxies if needed.
The proxy details online and telephone voting procedures, broker voting rules, and how quorum and vote thresholds are calculated. It also outlines the company’s governance structure, board committees, cybersecurity oversight, and 2025 executive pay, including salary and stock‑based awards for the CEO, Chief Innovation Officer and CFO.